Ketamine therapy at IMH for depression

The Institute of Mental Health in Singapore is now offering intravenous ketamine therapy as a standard medical service for patients battling treatment-resistant depression. This approach serves individuals for whom traditional antidepressants and other interventions have proven ineffective. By targeting glutamate receptors, this medical intervention stimulates brain cell connections and allows for a rapid reset of mood regulation pathways.

Consultant psychiatrist Dr. Goh Shih Ee notes that while standard oral medications often require weeks to show results, ketamine administered at sub-anaesthetic doses can produce improvements in mood and energy levels within days. The procedure involves a controlled 40-minute infusion, which provides clinicians with the ability to adjust dosing as needed for each patient. This specific method avoids certain side effects found in nasal spray alternatives.

Clinical data from the institute indicates that over half of the patients who received this treatment between late 2024 and mid-2026 experienced significant relief. These individuals reported a decrease in the intensity and frequency of suicidal thoughts. The protocol typically begins with an acute phase of eight sessions scheduled twice weekly, followed by a maintenance schedule determined by individual progress.

This treatment is reserved for those who have not responded to conventional antidepressants or other neurostimulation techniques. Candidates undergo assessment by specially trained psychiatrists to ensure safety and clinical appropriateness. The therapy is delivered in a strictly monitored hospital environment, which minimizes the risks associated with ketamine use.

Patients like Joseph Lim have reported success with the program after years of struggle with severe depressive symptoms. Following his participation, Lim noted a marked ability to manage his thoughts and re-enter the workforce. This service represents a shift in options for those dealing with persistent mental health challenges in Singapore.